Express Scripts bars 48 drugs for 2019

Express Scripts has announced its list of national preferred formulary exclusions for 2019. The list includes 48 drugs, including 22 that compete against generics, 12 whose competitors use the same active ingredient at a lower net price, and 11 that have cheaper brand or biosimilar versions.

Express Scripts has announced its list of national preferred formulary exclusions for 2019. The list includes 48 drugs, including 22 that compete against generics, 12 whose competitors use the same active ingredient at a lower net price, and 11 that have cheaper brand or biosimilar versions. The list of exclusions includes glecaprevir–pibrentasvir (Mavyret—AbbVie), sofosbuvir (Sovaldi—Gilead Sciences), and dabigatran etexilate mesylate (Pradaxa—Boehringer Ingelheim). On its web site, Express Scripts noted: "Despite promises to limit price increases, drugmakers are trying to game the market by delaying generic competition, blocking access to safe and effective biosimilars, and coyly deferring—not cancelling—list-price increases." The company added, "This is why our work to expand access and maximize value is more important now than ever."